RFA-CA-22-052: Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $500,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on February 17, 2023.
From the official notice on Grants.gov, last changed October 3, 2022. Checked November 7, 2026.
- Award ceiling$500,000
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU01
- Clinical trialsNot allowed
- Funded byNCI
- Median yearly award$630,694
- Typical project length5 years
- U01, Research Project Cooperative Agreement. Like an R01, but NIH staff are substantially involved in the work. Other open U01 notices.
Projects funded under RFA-CA-22-052 were run by National Cancer Institute (NCI, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-CA-22-052 in the NIH Guide.
Key dates
| Posted | October 3, 2022 |
|---|---|
| Deadline | February 17, 2023 |
| Archived by Grants.gov | March 25, 2023 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $630,694; it allows up to $500,000 per award.
- Most of the money in the 3 programs behind this notice (69% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
Through this Funding Opportunity Announcement (FOA), NCI, NIDA, and NCCIH invite Cooperative Agreement (U01) applications that propose prospective research studies to assess the benefits and harms of cannabis and cannabinoid use among adult cancer patients during active treatment. NCI, NIDA, and NCCIH are seeking well-designed prospective cohort studies of cancer patients with solid or hematologic tumors currently receiving treatment. Studies are expected to compare cancer patients who use cannabis/cannabinoids with cancer patients that do not use cannabis and/or cannabinoids. Research studies including diverse populations by age, sex, race/ethnicity, tumor types, and/or geography and propose population-based recruitment strategies using cancer registries are strongly encouraged. This FOA is published in parallel with RFA-CA-22-053 "Coordinating Center for Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U24 Clinical Trial Not Allowed). New prospective studies and the coordinating center funded under these FOAs will work together with NIH program staff.
Funded under RFA-CA-22-052 so far
NIH funded 5 projects under RFA-CA-22-052 in fiscal 2023 to 2026, at 5 institutions. The median yearly award was $630,694.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Assessing benefits and harms of cannabis use in patients treated with immunotherapy for cancer: a prospective cohort study | State University of New York at Buffalo | 2026 | $632,414 |
| A Prospective Cohort Study of Patients with Non-Small Cell Lung Cancer and Multiple Myeloma to Assess the Benefits and Harms Related to Cannabis Use During Treatment | Beckman Research Institute/City of Hope | 2026 | $603,058 |
| Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics | Wake Forest University Health Sciences | 2026 | $632,033 |
| Assessing Benefits and Harms of Medical Cannabis and Cannabinoid Use in Breast Cancer Patients During and After Treatments | University of Miami School of Medicine | 2026 | $650,251 |
| Longitudinal assessment of benefits and harms of cannabis use among community-based cancer patients during initial cancer treatment | Georgetown University | 2025 | $2.0 million |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Who has won Cancer Cause and Prevention Research grants before
From fiscal 2021 to 2025, Cancer Cause and Prevention Research (93.393) awarded $3.6 billion across 2,517 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | 81 | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | 65 | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | 48 | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | 51 | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | 49 | $76.1 million |
Who has won Research and Training in Complementary and Integrative Health grants before
From fiscal 2021 to 2025, Research and Training in Complementary and Integrative Health (93.213) awarded $575 million across 653 grant awards, an average of $880,790 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 15 | $25.9 million |
| The General Hospital Corporation | Massachusetts | 23 | $23.1 million |
| Duke University | North Carolina | 11 | $20.0 million |
| The Regents of the University of California, San Francisco | California | 16 | $15.2 million |
| Regents of the University of Minnesota | Minnesota | 13 | $15.0 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-CA-22-052 still open?
No. It closed on February 17, 2023.
Who can apply for Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Cannabis and Cannabinoid Use in Adult Cancer Patients During Treatment: Assessing Benefits and Harms (U01 Clinical Trial Not Allowed)?
Closed February 17, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $500,000 each.
Who has been funded under RFA-CA-22-052?
NIH RePORTER lists 5 projects funded under RFA-CA-22-052 in fiscal 2023 to 2026, at 5 institutions. The most were at State University of New York at Buffalo, Beckman Research Institute/City of Hope, Wake Forest University Health Sciences.
Who has won Research and Training in Complementary and Integrative Health grants before?
The largest recipients over five fiscal years were Yale Univ, The General Hospital Corporation, Duke University. The program made 653 awards worth $575 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Single Source for the Continuation of the Physiology of the Weight Reduced State (POWERS) Study (U01- Clinical Trials Required)
- Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
- Opportunities for Collaborative Research with the NIH Intramural Research Program (U01 Clinical Trial Optional)